Drug class
Anthraquinone derivative; symptomatic slow-acting medicine for osteoarthritis (SYSADOA)
Mechanism of action
Inhibits interleukin-1 beta activity and related inflammatory/catabolic pathways involved in cartilage degradation. It is a slow-acting agent and its clinical benefit may take several weeks to appear.
General use cases
- Symptomatic treatment of osteoarthritis of the hip or knee only, where authorised; not recommended for rapidly progressive hip OA. EMA restrictions: do not use in patients aged 65 years or older or in those with current or previous liver disease; stop treatment if diarrhoea occurs and monitor for hepatic injury.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
